Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ATBPD OTCMKTS:INVVY NASDAQ:RPTX NASDAQ:STTK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATBPDAntibe Therapeutics$0.22$2.64▼$3.50$1.21B0.5729,710 shsN/AINVVYIndivior$21.85-1.8%$21.85$14.76▼$35.50$3.01B0.353,825 shs8,100 shsRPTXRepare Therapeutics$1.77+0.3%$1.59$0.89▼$4.07$75.61M0.9495,886 shs36,477 shsSTTKShattuck Labs$1.79-6.8%$1.02$0.69▼$3.95$91.97M1.641.54 million shs327,172 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATBPDAntibe Therapeutics0.00%0.00%0.00%0.00%0.00%INVVYIndivior0.00%0.00%0.00%0.00%0.00%RPTXRepare Therapeutics+0.28%+3.22%+12.42%+24.30%-50.00%STTKShattuck Labs-6.77%-4.79%+79.00%+84.10%-53.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATBPDAntibe Therapeutics$0.22$2.64▼$3.50$1.21B0.5729,710 shsN/AINVVYIndivior$21.85-1.8%$21.85$14.76▼$35.50$3.01B0.353,825 shs8,100 shsRPTXRepare Therapeutics$1.77+0.3%$1.59$0.89▼$4.07$75.61M0.9495,886 shs36,477 shsSTTKShattuck Labs$1.79-6.8%$1.02$0.69▼$3.95$91.97M1.641.54 million shs327,172 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATBPDAntibe Therapeutics0.00%0.00%0.00%0.00%0.00%INVVYIndivior0.00%0.00%0.00%0.00%0.00%RPTXRepare Therapeutics+0.28%+3.22%+12.42%+24.30%-50.00%STTKShattuck Labs-6.77%-4.79%+79.00%+84.10%-53.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATBPDAntibe Therapeutics 0.00N/AN/AN/AINVVYIndivior 0.00N/AN/AN/ARPTXRepare Therapeutics 2.50Moderate Buy$4.50154.96% UpsideSTTKShattuck Labs 2.86Moderate Buy$4.00123.46% UpsideCurrent Analyst Ratings BreakdownLatest STTK, INVVY, ATBPD, and RPTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025STTKShattuck LabsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$4.008/14/2025STTKShattuck LabsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$4.00 ➝ $2.008/14/2025STTKShattuck LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATBPDAntibe Therapeutics$7.51M0.00N/AN/A$0.10 per share0.00INVVYIndivior$791M3.81$1.15 per share18.94$1.45 per share15.07RPTXRepare Therapeutics$53.48M1.42N/AN/A$3.56 per share0.50STTKShattuck Labs$5.72M14.99N/AN/A$1.67 per share1.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATBPDAntibe Therapeutics-$14.54M-$0.60N/AN/AN/A-273.96%-150.49%-98.51%N/AINVVYIndivior$205M$1.0520.8112.00N/AN/AN/AN/AN/ARPTXRepare Therapeutics-$84.69M-$2.58N/AN/AN/AN/A-78.25%-66.85%11/6/2025 (Estimated)STTKShattuck Labs-$75.41M-$1.21N/AN/AN/AN/A-81.80%-71.46%11/13/2025 (Estimated)Latest STTK, INVVY, ATBPD, and RPTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025STTKShattuck Labs-$0.25-$0.24+$0.01-$0.24N/AN/A8/8/2025Q2 2025RPTXRepare Therapeutics-$0.56-$0.39+$0.17-$0.39$2.50 million$0.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATBPDAntibe TherapeuticsN/AN/AN/AN/AN/AINVVYIndiviorN/AN/AN/AN/AN/ARPTXRepare TherapeuticsN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATBPDAntibe TherapeuticsN/A5.975.42INVVYIndiviorN/AN/AN/ARPTXRepare TherapeuticsN/A6.306.30STTKShattuck LabsN/A10.2510.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATBPDAntibe TherapeuticsN/AINVVYIndivior0.05%RPTXRepare Therapeutics85.09%STTKShattuck Labs58.74%Insider OwnershipCompanyInsider OwnershipATBPDAntibe TherapeuticsN/AINVVYIndiviorN/ARPTXRepare Therapeutics11.50%STTKShattuck Labs12.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATBPDAntibe Therapeutics47387.00 millionN/ANot OptionableINVVYIndivior800137.88 millionN/ANot OptionableRPTXRepare Therapeutics18042.96 million38.02 millionOptionableSTTKShattuck Labs10047.90 million42.16 millionOptionableSTTK, INVVY, ATBPD, and RPTX HeadlinesRecent News About These CompaniesShattuck Labs (NASDAQ:STTK) Rating Increased to Hold at Wall Street ZenSeptember 15 at 2:07 AM | marketbeat.comShattuck Labs (NASDAQ:STTK) Upgraded at Wall Street ZenSeptember 14 at 3:55 AM | americanbankingnews.comShattuck Labs, Inc. (NASDAQ:STTK) Receives $4.00 Average Price Target from BrokeragesSeptember 13 at 3:17 AM | americanbankingnews.comQ3 Earnings Forecast for Shattuck Labs Issued By WedbushSeptember 12, 2025 | marketbeat.comQ3 Earnings Estimate for Shattuck Labs Issued By WedbushSeptember 11, 2025 | americanbankingnews.comShattuck Labs (NASDAQ:STTK) Coverage Initiated by Analysts at WedbushSeptember 10, 2025 | marketbeat.comShattuck Labs, Inc. (NASDAQ:STTK) Given Average Rating of "Moderate Buy" by AnalystsSeptember 10, 2025 | marketbeat.comWedbush Initiates Coverage on Shattuck Labs (NASDAQ:STTK)September 10, 2025 | americanbankingnews.comWedbush Initiates Coverage of Shattuck Labs (STTK) with Outperform RecommendationSeptember 9, 2025 | msn.comShattuck Labs (STTK) Upgraded to Buy: What Does It Mean for the Stock?September 8, 2025 | zacks.comWall Street Zen Upgrades Shattuck Labs (NASDAQ:STTK) to "Hold"September 8, 2025 | marketbeat.comShattuck Labs (NASDAQ:STTK) Stock Rating Upgraded by Wall Street ZenSeptember 7, 2025 | americanbankingnews.comShort Interest in Shattuck Labs, Inc. (NASDAQ:STTK) Grows By 196.4%September 6, 2025 | americanbankingnews.comShattuck Labs (NASDAQ:STTK) Director Mona Ashiya Buys 6,306,127 SharesSeptember 3, 2025 | insidertrades.comOrbiMed Advisors buys Shattuck Labs (STTK) shares worth $5.47 millionSeptember 3, 2025 | investing.comAshiya Mona buys Shattuck Labs (STTK) shares worth $5.47 millionSeptember 3, 2025 | investing.comShattuck Labs Closes $103M Private Placement DealAugust 26, 2025 | msn.comShattuck Labs Secures $103 Million in Private Placement to Advance SL-325 for Autoimmune Diseases and Appoints New Board MembersAugust 26, 2025 | quiverquant.comQShattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of DirectorsAugust 26, 2025 | globenewswire.comShattuck Labs, Inc.: Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel DiseaseAugust 22, 2025 | finanznachrichten.deShattuck Labs says IND for SL-325 for treatment of IBD in effectAugust 22, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTTK, INVVY, ATBPD, and RPTX Company DescriptionsAntibe Therapeutics OTCMKTS:ATBPDAntibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.Indivior OTCMKTS:INVVY$21.85 -0.40 (-1.82%) As of 06/9/2023Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.Repare Therapeutics NASDAQ:RPTX$1.76 +0.01 (+0.28%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.76 0.00 (-0.28%) As of 09/15/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.Shattuck Labs NASDAQ:STTK$1.79 -0.13 (-6.77%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.80 +0.01 (+0.84%) As of 09/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
